Genetically engineered human islets protected from CD8-mediated autoimmune destruction in vivo

Molecular Therapy

Volumn 21, Issue 8, 2013, Pages 1592-1601

  Zaldumbide, Arnaud ^a   Alkemade, Gonnie ^a,b   Carlotti, Françoise ^a   Nikolic, Tatjana ^a   Abreu, Joana R F ^a   Engelse, Marten A ^a   Skowera, Anja ^c,d   De Koning, Eelco J ^a   Peakman, Mark ^c,d   Roep, Bart O ^a   Hoeben, Rob C ^a   Wiertz, Emmanuel J H J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CD8 ANTIGEN; CELL PROTEIN; IMMUNEVASIN; INSULIN; LENTIVIRUS VECTOR; SERINE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR 9; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CELL CLONE; CELL DESTRUCTION; CELL KILLING; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DIABETES MELLITUS; DNA MODIFICATION; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; INSULIN SYNTHESIS; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PANCREAS ISLET TRANSPLANTATION; PROTECTION; PROTEIN EXPRESSION; PROTEIN SECRETION; REPORTER GENE;

HERPESVIRIDAE; HUMAN HERPESVIRUS 5; MUS;

ANIMALS; AUTOIMMUNITY; C-PEPTIDE; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DIABETES MELLITUS, TYPE 1; GENE EXPRESSION; GENE ORDER; GENETIC VECTORS; HLA-A2 ANTIGEN; HUMANS; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; LENTIVIRUS; MALE; MICE; ORGAN SPECIFICITY; PROMOTER REGIONS, GENETIC; PROTEIN PRECURSORS; SERPINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; VIRAL ENVELOPE PROTEINS;

EID: 84881316825     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.105     Document Type: Article

References (50)

1. In't Veld, P, Lievens, D, De Grijse, J, Ling, Z, Van der Auwera, B, Pipeleers-Marichal, M et al. (2007). Screening for insulitis in adult autoantibody-positive organ donors. Diabetes 56: 2400-2404.
2. Cnop, M, Welsh, N, Jonas, JC, Jörns, A, Lenzen, S and Eizirik, DL (2005). Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: Many differences, few similarities. Diabetes 54 Suppl 2: S97-107.
3. Coppieters, KT, Dotta, F, Amirian, N, Campbell, PD, Kay, TW, Atkinson, MA et al. (2012). Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 209: 51-60.
4. Katz, J, Benoist, C and Mathis, D (1993). Major histocompatibility complex class I molecules are required for the development of insulitis in non-obese diabetic mice. Eur J Immunol 23: 3358-3360.
5. Serreze, DV, Leiter, EH, Christianson, GJ, Greiner, D and Roopenian, DC (1994). Major histocompatibility complex class I-deficient NOD-B2mnull mice are diabetes and insulitis resistant. Diabetes 43: 505-509.
6. Wicker, LS, Leiter, EH, Todd, JA, Renjilian, RJ, Peterson, E, Fischer, PA et al. (1994). Beta 2-microglobulin-deficient NOD mice do not develop insulitis or diabetes. Diabetes 43: 500-504.
7. Hamilton-Williams, EE, Palmer, SE, Charlton, B and Slattery, RM (2003). Beta cell MHC class I is a late requirement for diabetes. Proc Natl Acad Sci USA 100: 6688-6693.
8. Kay, TW, Parker, JL, Stephens, LA, Thomas, HE and Allison, J (1996). RIP-beta 2-microglobulin transgene expression restores insulitis, but not diabetes, in beta 2-microglobulin null nonobese diabetic mice. J Immunol 157: 3688-3693.
9. Chervonsky, AV, Wang, Y, Wong, FS, Visintin, I, Flavell, RA, Janeway, CA Jr et al. (1997). The role of Fas in autoimmune diabetes. Cell 89: 17-24.
10. Apostolou, I, Hao, Z, Rajewsky, K and von Boehmer, H (2003). Effective destruction of Fas-deficient insulin-producing beta cells in type 1 diabetes. J Exp Med 198: 1103-1106.
11. Kägi, D, Odermatt, B, Ohashi, PS, Zinkernagel, RM and Hengartner, H (1996). Development of insulitis without diabetes in transgenic mice lacking perforindependent cytotoxicity. J Exp Med 183: 2143-2152.
12. Thomas, HE, Trapani, JA and Kay, TW (2010). The role of perforin and granzymes in diabetes. Cell Death Differ 17: 577-585.
13. Roep, BO and Atkinson, M (2004). Animal models have little to teach us about type 1 diabetes: 1. In support of this proposal. Diabetologia 47: 1650-1656.
14. Roep, BO, Atkinson, M and von Herrath, M (2004). Satisfaction (not) guaranteed: Reevaluating the use of animal models of type 1 diabetes. Nat Rev Immunol 4: 989-997.
15. Harlan, DM, Kenyon, NS, Korsgren, O and Roep, BO; Immunology of Diabetes Society (2009). Current advances and travails in islet transplantation. Diabetes 58: 2175-2184.
16. Pinkse, GG, Tysma, OH, Bergen, CA, Kester, MG, Ossendorp, F, van Veelen, PA et al. (2005). Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci USA 102: 18425-18430.
17. Huurman, VA, Hilbrands, R, Pinkse, GG, Gillard, P, Duinkerken, G, van de Linde, P et al. (2008). Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS ONE 3: E2435.
18. Huurman, VA, Velthuis, JH, Hilbrands, R, Tree, TI, Gillard, P, van der Meer-Prins, PM et al. (2009). Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation. Am J Transplant 9: 382-388.
19. Hilbrands, R, Huurman, VA, Gillard, P, Velthuis, JH, De Waele, M, Mathieu, C et al. (2009). Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes 58: 2267-2276.
20. Blondet, JJ, Carlson, AM, Kobayashi, T, Jie, T, Bellin, M, Hering, BJ et al. (2007). The role of total pancreatectomy and islet autotransplantation for chronic pancreatitis. Surg Clin North Am 87: 1477-501, x.
21. Griffin, BD, Verweij, MC and Wiertz, EJ (2010). Herpesviruses and immunity: The art of evasion. Vet Microbiol 143: 89-100.
22. Horst, D, Verweij, MC, Davison, AJ, Ressing, ME and Wiertz, EJ (2011). Viral evasion of T cell immunity: Ancient mechanisms offering new applications. Curr Opin Immunol 23: 96-103.
23. Zaldumbide, A and Hoeben, RC (2008). How not to be seen: Immune-evasion strategies in gene therapy. Gene Ther 15: 239-246.
24. Wiertz, EJ, Tortorella, D, Bogyo, M, Yu, J, Mothes, W, Jones, TR et al. (1996). Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 384: 432-438.
25. Medema, JP, de Jong, J, Peltenburg, LT, Verdegaal, EM, Gorter, A, Bres, SA et al. (2001). Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA 98: 11515-11520.
26. Carlotti, F, Zaldumbide, A, Loomans, CJ, van Rossenberg, E, Engelse, M, de Koning, EJ et al. (2010). Isolated human islets contain a distinct population of mesenchymal stem cells. Islets 2: 164-173.
27. Bishop, AE and Polak, JM (1997). The Anatomy, Organisation and Ultrastructure of the Islets of Langerhans. Blackwell Science: Oxford.
28. Skowera, A, Ellis, RJ, Varela-Calviño, R, Arif, S, Huang, GC, Van-Krinks, C et al. (2008). CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 118: 3390-3402.
29. Kobinger, GP, Deng, S, Louboutin, JP, Vatamaniuk, M, Matschinsky, F, Markmann, JF et al. (2004). Transduction of human islets with pseudotyped lentiviral vectors. Hum Gene Ther 15: 211-219.
30. Callewaert, H, Gysemans, C, Cardozo, AK, Elsner, M, Tiedge, M, Eizirik, DL et al. (2007). Cell loss during pseudoislet formation hampers profound improvements in islet lentiviral transduction efficacy for transplantation purposes. Cell Transplant 16: 527-537.
31. O'Sullivan, ES, Johnson, AS, Omer, A, Hollister-Lock, J, Bonner-Weir, S, Colton, CK et al. (2010). Rat islet cell aggregates are superior to islets for transplantation in microcapsules. Diabetologia 53: 937-945.
32. Jerome, KR, Sloan, DD and Aubert, M (2003). Measurement of CTL-induced cytotoxicity: The caspase 3 assay. Apoptosis 8: 563-571.
33. O'Brien, MA, Daily, WJ, Hesselberth, PE, Moravec, RA, Scurria, MA, Klaubert, DH et al. (2005). Homogeneous, bioluminescent protease assays: Caspase-3 as a model. J Biomol Screen 10: 137-148.
34. Kanno, A, Umezawa, Y and Ozawa, T (2009). Detection of apoptosis using cyclic luciferase in living mammals. Methods Mol Biol 574: 105-114.
35. Kleijwegt, FS, Laban, S, Duinkerken, G, Joosten, AM, Koeleman, BP, Nikolic, T et al. (2011). Transfer of regulatory properties from tolerogenic to proinflammatory dendritic cells via induced autoreactive regulatory T cells. J Immunol 187: 6357-6364.
36. O'Sullivan, ES, Vegas, A, Anderson, DG and Weir, GC (2011). Islets transplanted in immunoisolation devices: A review of the progress and the challenges that remain. Endocr Rev 32: 827-844.
37. Carter, JD, Ellett, JD, Chen, M, Smith, KM, Fialkow, LB, McDuffie, MJ et al. (2005). Viral IL-10-mediated immune regulation in pancreatic islet transplantation. Mol Ther 12: 360-368.
38. Hollander, K, Bar-Chen, M and Efrat, S (2005). Baculovirus p35 increases pancreatic beta-cell resistance to apoptosis. Biochem Biophys Res Commun 332: 550-556.
39. Kojaoghlanian, T, Joseph, A, Follenzi, A, Zheng, JH, Leiser, M, Fleischer, N et al. (2009). Lentivectors encoding immunosuppressive proteins genetically engineer pancreatic beta-cells to correct diabetes in allogeneic mice. Gene Ther 16: 340-348.
40. Lu, B, Wu, H, Gu, P, Du, H, Shao, J, Wang, J et al. (2012). Improved glucosestimulated insulin secretion by intra-islet inhibition of protein-tyrosine phosphatase 1B expression in rats fed a high-fat diet. J Endocrinol Invest 35: 63-70.
41. Fenjves, ES, Ochoa, MS, Cechin, S, Gay-Rabinstein, C, Pérez-Alvarez, I, Ichii, H et al. (2008). Protection of human pancreatic islets using a lentiviral vector expressing two genes: CFLIP and GFP. Cell Transplant 17: 793-802.
42. Wiertz, E, Hill, A, Tortorella, D and Ploegh, H (1997). Cytomegaloviruses use multiple mechanisms to elude the host immune response. Immunol Lett 57: 213-216.
43. Wiertz, EJ, Mukherjee, S and Ploegh, HL (1997). Viruses use stealth technology to escape from the host immune system. Mol Med Today 3: 116-123.
44. Barel, MT, Pizzato, N, Le Bouteiller, P, Wiertz, EJ and Lenfant, F (2006). Subtle sequence variation among MHC class I locus products greatly influences sensitivity to HCMV US2- and US11-mediated degradation. Int Immunol 18: 173-182.
45. Falk, CS, Mach, M, Schendel, DJ, Weiss, EH, Hilgert, I and Hahn, G (2002). NK cell activity during human cytomegalovirus infection is dominated by US2-11-mediated HLA class I down-regulation. J Immunol 169: 3257-3266.
46. Knight, RR, Kronenberg, D, Zhao, M, Huang, GC, Eichmann, M, Bulek, A et al. (2013). Human ß-cell killing by autoreactive preproinsulin-specific CD8 T cells is predominantly granule-mediated with the potency dependent upon T-cell receptor avidity. Diabetes 62: 205-213.
47. Shultz, LD, Ishikawa, F and Greiner, DL (2007). Humanized mice in translational biomedical research. Nat Rev Immunol 7: 118-130.
48. Brooks, AR, Harkins, RN, Wang, P, Qian, HS, Liu, P and Rubanyi, GM (2004). Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med 6: 395-404.
49. de la Garza-Rodea, AS, Verweij, MC, Boersma, H, van der Velde-van Dijke, I, de Vries, AA, Hoeben, RC et al. (2011). Exploitation of herpesvirus immune evasion strategies to modify the immunogenicity of human mesenchymal stem cell transplants. PLoS One 6: E14493.
50. Carlotti, F, Bazuine, M, Kekarainen, T, Seppen, J, Pognonec, P, Maassen, JA et al. (2004). Lentiviral vectors efficiently transduce quiescent mature 3T3-L1 adipocytes. Mol Ther 9: 209-217.